ClinicalTrials.gg
CompletedNCT07408518Updated Oct 19, 2026

Impact of B. Adolescentis iVS-1 Probiotic on Gastrointestinal Outcomes

An interventional study of Probiotic and Placebo in Digestive Disease and Gut Health, sponsored by Synbiotic Health. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Synbiotic Health · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The study team is conducting a consumer-driven, decentralized clinical research study to assess the impact of the consumer-grade probiotic supplement, iVS-1, on adults with moderate to severe gastrointestinal discomfort. Bifidobacterium adolescentis iVS-1 was chosen for its association with gastrointestinal health benefits and its safety profile, having been self-affirmed as GRAS and lacking antibiotic resistance and virulence genes. The study aims to evaluate the probiotic's effects not only on gastrointestinal symptoms but also on secondary outcomes like sleep disturbance, sleep quality, daytime alertness, anxiety, stress, and gut microbiota. This will be accomplished using self-reported outcome questionnaires, daily surveys, and at-home stool collection over a period of up to 17 weeks. There is no "doctor-patient" relationship, as participants are making an informed choice to take the product as consumers and participate in the process. Findings will contribute to knowledge about the probiotic's tolerability, formulation, and the design of future studies.

Read the detailed description

The probiotic strain, Bifidobacterium adolescentis iVS-1, was isolated from a healthy adult after consumption of the prebiotic galactooligosaccharides (GOS). Genome sequencing confirmed the absence of antibiotic resistance and virulence genes in iVS-1. Clinical trials have shown that the strain can improve gut barrier function and reduce symptoms associated with lactose tolerance.

The rationale for the current study is to observe the impact of the iVS-1 probiotic supplement on gastrointestinal symptoms and its effects on various measures of health that can be collected in a home setting. The study team will examine outcomes in a broad age range of adults who have chosen to try the product. The primary objective is to evaluate the impact of the iVS-1 Probiotic study product on gastrointestinal symptoms (i.e., flatulence, bloating, abdominal discomfort). Secondary objectives include evaluating the impact of iVS-1 on daily gastrointestinal symptoms, anxiety (using the Generalized Anxiety Disorder-7 or GAD-7 score), sleep disturbance (using the Insomnia Sleep Index or ISI score), sleep quality, daytime alertness, and stress. The study will also observe the tolerability of the product and explore its impact on gut microbiota composition and function and identify improvements for future participant-centered study designs.

Participants, who must have self-reported moderate to severe gastrointestinal or digestive symptoms, will be randomized to one of two groups: iVS-1 Probiotic Supplement or matching placebo. The Investigators, study team, and participants will be blinded to the group assignment. The study consists of a screening period, randomization and shipping period, a baseline period, a 6-week product/placebo use period, and a 4-week follow-up period. Data will be collected remotely using the Chloe mobile app, which is People Science's web-based data collection platform. Assessments include the Gastrointestinal Symptom Rating Scale (GSRS), GAD-7, and ISI, administered at baseline and at the end of weeks 2, 4, and 6 during the product use period. Daily surveys will collect data on gastrointestinal symptoms, sleep quality, waking alertness, and stress using a 10-point visual analogue scale (VAS). At-home stool collections will be completed during baseline and at the end of the study product/placebo use period (Day 49) to assess changes in gut microbiota.

02

Conditions studied

  • Digestive Disease
  • Gut Health

Keywords

  • Digestive Symptoms
  • Bloating
  • Gas
  • Abdominal Pain
  • Flatulence
  • Constipation
  • Diarrhea
03

In context

Digestive System Diseases

406 studies on the registry are indexed under Digestive System Diseases; 79 are open to participants now.

This study's enrollment of 92 is close to the median of 86 across 289 interventional studies indexed under Digestive System Diseases.

Browse Digestive System Diseases studies →

Lead sponsor

Synbiotic Health is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18-75 years old, inclusive.
  • Has self-reported moderate to severe gastrointestinal or digestive symptoms, such as abdominal pain, bloating, flatulence, constipation, or diarrhea.
  • Has a Gastrointestinal Symptom Rating Scale (GSRS) score between 4-7, not driven primarily by symptoms of reflux (whereby reflux does not make up more than 60% of GSRS total score).
  • Willingness to refrain from taking probiotics or prebiotics during the study period.
  • Interested in understanding more about their gut health and the use probiotic products.
  • If taking any OTC or prescription medications for anxiety (e.g. magnesium, anticholinergics, Buspirone, Tricyclics, MAOIs,) or other class of medication for anxiety, must be on a stable dose for at least 4 weeks prior to randomization and throughout the course of the study.
  • If using any cannabis-containing products, must be on a stable dose regimen for at least 4 weeks prior to randomization and throughout the course of the study.
  • If using any nicotine-containing products, must be on a stable regimen for at least 4 weeks prior to randomization and throughout the course of the study.
  • In good general health at the time of screening (Investigator discretion).
  • Able to read and understand English.
  • Able to read, understand, and provide .
  • Able to use a personal smartphone device and download Chloe by People Science.
  • Able to receive shipment of the product at an address within the United States.
  • Able to complete study assessments over the course of up to 17 weeks.

Exclusion criteria

Exclusion Criteria:

  • Do not have a personal smartphone, internet access, or unwilling to download Chloe.
  • Currently on a carnivore diet, raw food diet, fruitarian, liquid diet (does not include vegans or vegetarians).
  • Concomitant Therapies:

    1. Participants receiving any therapies or treatments within 30 days prior to randomization.
    2. Participants currently taking or have taken antibiotics, probiotic, or prebiotic supplements within the past 4 weeks prior to randomization.
    3. Participants using medications, systemic , antifungals or other medications known to significantly impact gastrointestinal function or microbiota.
  • Other Illnesses or Conditions: Participants who have the following comorbidities or gastrointestinal illnesses are excluded:

    1. Participants with a clinical diagnosis of any gastrointestinal illness, including but not limited to:

      • Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
      • Gastroesophageal reflux disease (GERD)
      • Gastric or duodenal ulcers
      • Celiac disease
      • Diverticular disease
      • Chronic pancreatitis
      • Gastroparesis
      • Severe liver disease (e.g., cirrhosis, hepatitis, NAFLD acceptable)
      • Gallbladder disease (e.g., cholecystitis, cholelithiasis)
      • Gastrointestinal cancer (Colorectal, Intestinal, Stomach, Liver, Gallbladder)
    2. Participants with a known or suspected gastrointestinal infection, such as:

      • Clostridium difficile infection
      • Helicobacter pylori infection
      • Parasitic infections (e.g., Giardia, Cryptosporidium)
    3. Participants with a history of gastrointestinal surgery, excluding appendectomy and cholecystectomy.
    4. Participants with a history of gastrointestinal bleeding or perforation.
    5. Currently diagnosed with Alcohol Use Disorder and/or Substance Use Disorder.
    6. Currently pregnant, planning to become pregnant in the next 1 month, or breastfeeding.
    7. Any underlying medical conditions or comorbidities that may confound the assessment of digestive symptoms or the evaluation of the study outcomes.
    8. Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes.
  • Known or previous allergic reaction to Bifidobacterium adolescentis, microcrystalline cellulose, the capsule material (hydroxypropylmethylcellulose), magnesium stearate and silicon dioxide.
  • Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
92 participants (actual)

Study arms

  • Active comparator
    Active

    Participants will be randomized to one of two groups A or B: (1) IVS-1 Probiotic Supplement, and (2) Matching placebo. The Investigators, the study team and participants will be blinded to the group assignment.

    Dietary Supplement: Probiotic

  • Placebo comparator
    Placebo

    Participants will be randomized to one of two groups A or B: (1) IVS-1 Probiotic Supplement, and (2) Matching placebo. The Investigators, the study team and participants will be blinded to the group assignment.

    Other: Placebo

Interventions

  • Dietary supplementProbiotic

    Participants will be randomized to one of two groups A or B: (1) IVS-1 Probiotic Supplement, and (2) Matching placebo. The Investigators, the study team and participants will be blinded to the group assignment.

  • OtherPlacebo

    An inactive substance that looks similar to the product being tested, however has no specific therapeutic effect to the condition being tested.

06

What researchers measure

Primary outcomes

  1. Impact on Gastrointestinal Symptoms

    The primary objective of this study is to evaluate the impact of the iVS-1 Probiotic study product on gastrointestinal symptoms, such as flatulence, bloating, and abdominal discomfort. This goal will be measured by the change in the mean total score on the Gastrointestinal Symptom Rating Scale (GSRS) between the study product and placebo groups during the study period. The study product/placebo use period is 6 weeks. Baseline period will be compared as well.

    Time frame: 6 weeks

Secondary outcomes

  1. Daily Gastrointestinal Symptoms

    The goal is to evaluate the impact of the iVS-1 Probiotic study product on daily gastrointestinal symptoms (i.e., flatulence, bloating, abdominal discomfort). This will be measured by the change in mean GSRS scores between placebo and study product groups: 1. Scores by individual dimension (diarrhea, indigestion, constipation, abdominal pain and reflux). 2. Composite scores at Week 2 and Week 4. Baseline period will be compared as well.

    Time frame: 6-week

  2. Tolerability of Drug

    The goal is to observe the tolerability of the iVS-1 Probiotic study product. This will be measured by the assessment of the number, frequency, and severity of adverse events (AEs), serious adverse events (SAEs), and AE withdrawals reported over the study product/placebo use period. This is monitored over the 6-week product/placebo use period.

    Time frame: 6 weeks

  3. Anxiety

    The goal is to evaluate the impact of the iVS-1 Probiotic study product on anxiety. This will be measured by the change in the Generalized Anxiety Disorder-7 (GAD-7) score between the placebo and study product group. Baseline period will be compared as well.

    Time frame: 6-weeks

  4. Sleep Disturbances

    The goal is to evaluate the impact of the iVS-1 Probiotic study product on sleep disturbance. This will be measured by the change in the Insomnia Severity Index (ISI) score between the placebo and study product group. Baseline period will be compared as well.

    Time frame: 6 weeks

  5. Sleep Quality

    The goal is to evaluate the impact of the iVS-1 Probiotic study product on sleep quality. This will be measured by the change in average sleep quality score between the placebo and study product group, as assessed by a daily 10-point Visual Analogue Scale (VAS). Baseline period will be compared as well.

    Time frame: 6 weeks

  6. Daytime Alertness

    The goal is to evaluate the impact of the iVS-1 Probiotic study product on daytime alertness. This will be measured by the change in average restedness score between the placebo and study product group, as assessed by a daily 10-point VAS scale. Baseline period will be compared as well.

    Time frame: 6 weeks

  7. Stress

    The goal is to evaluate the impact of the iVS-1 Probiotic study product on stress. This will be measured by the change in average stress score between the study product and placebo group, as assessed by a daily 10-point VAS scale. Baseline period will be compared as well.

    Time frame: 6 Week

Other outcomes

  1. Impact on gut microbiota

    To evaluate the impact of iVS-1 Probiotic study product on gut microbiota composition and function by looking at the change from baseline in gut microbiome, specifically in probiotic species of Bifidobacteria and quantity of B. adolescentis, between placebo and study product group at Week 6 as measured and analyzed from stool specimens.

    Time frame: 6 weeks

07

Study locations

1 site
  • People Science, Inc.
    Los Angeles, California 90045, United States
08

References and documents

Individual participant data

Plan to share: Undecided — There is no plan currently to share IPD with other researchers.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2026 to primary completion in Jul 2026, 5 months.

Of 78 interventional studies with no phase under Digestive System Diseases, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 57. This study's 5 months is below that.

Digestive System Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2026, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Feb 13, 2026
StartActual
Jan 20, 2026
Primary completionActual
Jul 13, 2026
CompletionActual
Aug 13, 2026was Sep 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 19, 2026
Primary completion
Jul 27, 2026→Jul 13, 2026 (actual)
Oct 19, 2026
Study completion
Sep 23, 2026→Aug 13, 2026 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Active, not recruiting→Completed
    Primary completion Jul 27, 2026→Jul 13, 2026 (now actual)
    Study completion Sep 23, 2026→Aug 13, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07408518
Lead sponsor
Synbiotic Health
Collaborators
People Science, Inc.
Responsible party
Sponsor
First posted
Feb 13, 2026
Start date
Jan 20, 2026
Primary completion
Jul 13, 2026
Completion
Aug 13, 2026
Last update
Oct 19, 2026

Study contacts

Noah Craft, MD
principal investigator · People Science, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion